Crinetics Pharmaceuticals Inc (CRNX) Stock Analysis
Verdict: WATCH (do not buy)
Paltusotine phase III success is priced in; the 98% jump creates an 'air pocket' risk despite the strong endocrine pipeline potential.
Investment score: 58/100
Analysis as of
Is Crinetics Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
CRNX has transitioned to a mid-cap biotech but faces technical exhaustion after a 98% daily gain.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Crinetics Pharmaceuticals Inc opportunities and risks
What speaks for CRNX
- Paltusotine Market Capture
What speaks against CRNX
- Mean Reversion After Parabolic Move
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CRNX | n/a | 487.4x | n/a | 98.9% | -2747.2% | -4.8% |
| AXSM | n/a | 18.1x | n/a | 92.6% | -26.6% | -0.6% |
| ELAN | n/a | 2.5x | 20.8x | 49.4% | -4.9% | 2.6% |
| CORT | 209.0x | 13.1x | 706.2x | 98.3% | 6.2% | 1.2% |
| LQDA | 339.7x | 25.1x | 133.6x | 91.8% | 7.7% | 0.6% |
| LGND | 40.7x | 23.3x | 30.3x | 98.6% | 55.9% | 1.9% |
| Peer median | 40.7x | 18.1x | 30.3x | 92.6% | 6.2% | 1.2% |
Frequently asked questions about Crinetics Pharmaceuticals Inc (CRNX)
Is CRNX stock a good investment?
The TradeMates model rates Crinetics Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 58/100. CRNX has transitioned to a mid-cap biotech but faces technical exhaustion after a 98% daily gain. This is algorithmic model output, not personal investment advice.
Is CRNX stock a buy?
The TradeMates model verdict for CRNX is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.